



Press release December 2nd, 2009

Biovitrum AB (publ) announces terms of the rights issue

Read the whole press release at:

<http://www.biovitrum.com/templates/InformationPage.aspx?id=818>

For further information, please contact:

Biovitrum AB (publ)

Martin Nicklasson, CEO
Phone: +46 8 697 20 00

Göran Arvidson, CFO
Phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com

About Biovitrum

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. Biovitrum has revenues of approximately SEK 1.2 billion and approximately 400 employees (prior to the Transaction). Biovitrum's head office is located in Sweden and the share is listed on the NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com.

The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 8:00 CET on December 2nd, 2009.